Hepatotoxicity with Adalimumab: What Hidradenitis Suppurativa Patients Must Know

---

My name is Jaap, and I am a biomedical scientist that also used to live with severe Hidradenitis Suppurativa, the kind that takes over your life. Today, I am completely asymptomatic because I learned how to heal Hidradenitis Suppurativa from within. More importantly, I’ve had the privilege of helping many other individuals with HS get their lives back, too.

Introduction: When the Treatment Becomes the Problem

For many battling the relentless pain and inflammation of Hidradenitis Suppurativa (HS), biologic drugs like Adalimumab (often known by the brand name Humira) can feel like a lifeline. They represent modern medicine’s most powerful tools for quieting the immune system’s storm. But what happens when the very shield designed to protect you causes unexpected harm?

It’s a reality we need to confront. While incredibly helpful for some, these powerful drugs come with potential risks. A recent case report published in Dermatology Practical & Conceptual brings one such risk into sharp focus for the HS community: drug-induced liver injury (DILI), also known as hepatotoxicity [1]. This short but significant paper details the experiences of two HS patients who developed liver problems while on Adalimumab.

Today, we’re going to respectfully unpack what these researchers found. This isn’t about fear-mongering; it’s about empowerment through knowledge. Understanding the potential downsides of relying solely on symptom-suppressing treatments reinforces why addressing the root cause of HS, the underlying fire of inflammation, is not just an option, but a necessity for true, sustainable healing. Let’s explore what this means for how we approach treating Hidradenitis Suppurativa.

Adalimumab: A Powerful Shield with Known Complexities

First, let’s be clear: Adalimumab is a significant advancement in managing inflammatory diseases. As a TNF-alpha inhibitor, it works by blocking one of the key inflammatory signals (cytokines) that drive the destructive cycle in conditions like HS. For many, it can reduce the number and severity of painful abscesses and nodules, offering much-needed relief.

However, like any intervention that powerfully modulates the immune system, it doesn’t come without potential complications. Hepatotoxicity, or liver damage, has been documented as a possible adverse effect, although the exact mechanisms aren’t always fully understood. This new report is important because, according to the authors, it describes the first specific cases of Adalimumab-associated DILI in patients being treated for HS.

The Study: Two HS Patients, Two Alarming Liver Reactions

The paper by Dr. Cristian Fernando Caballero-Linares and colleagues presents two distinct cases that highlight the unpredictable nature of this side effect:

1. Case 1 (Delayed Onset): A 47-year-old woman with severe (Hurley Stage III) HS started Adalimumab after initial treatment with antibiotics. She was on the therapy (including switching to a biosimilar) for over two years before developing discomfort and significantly elevated liver enzymes (transaminases five times the normal limit). Tests revealed severe fatty liver (steatosis), which hadn’t been present before. Her liver function improved after stopping Adalimumab and receiving corticosteroids.
2. Case 2 (Acute Onset): A 56-year-old woman, also with Hurley Stage III HS, had a much more dramatic reaction. Just three days after receiving her very first induction dose of Adalimumab (160 mg), she developed severe epigastric pain. Her liver enzymes reached alarming levels (ALT 1595 U/L, AST 587 U/L, GGT 556 U/L). To put that in perspective, these levels can be more than 30 times higher than the typical upper limit of normal for some enzymes, indicating significant liver distress. Adalimumab was immediately stopped, and thankfully, her liver enzymes gradually returned to normal. The diagnosis was DILI caused by the recent Adalimumab initiation.

These two stories underscore a crucial point: Adalimumab-induced liver injury doesn’t follow a set timeline. It can appear years into treatment or strike almost immediately after the first dose. This unpredictability points towards what researchers call an idiosyncratic reaction, meaning it’s likely driven by an individual’s unique immune response to the drug, rather than the dose itself.

Why Does This Happen? The Unpredictable Nature of Immune Suppression

The exact biological reason why Adalimumab causes liver injury in some individuals isn’t fully mapped out. The researchers suggest it might involve an abnormal immune response triggered by the very act of blocking TNF-alpha. This blockade could potentially lead to unexpected inflammation in the liver.

What is clear from these cases, and supported by other research the authors cite, is that stopping the drug promptly is crucial once liver abnormalities appear. This allows the liver a chance to recover. This reinforces the paper’s conclusion: routine liver monitoring is essential, especially when starting Adalimumab therapy.

The “Knowledge Gap”: Silencing the Alarm vs. Extinguishing the Fire

This research, while focused on a specific side effect, perfectly illustrates the limitations of a purely symptom-focused approach to HS, what I call the “knowledge gap” in conventional medicine.

Adalimumab is a powerful tool for silencing the smoke alarm, the downstream inflammatory signals like TNF-alpha that cause the painful lesions. It acts as a temporary shield. But these two cases are a stark reminder that even the strongest shields can have vulnerabilities or cause collateral damage. The core issue, the fire of systemic, body-wide inflammation that drives HS, remains unaddressed by the drug itself.

When the body is in a state of chronic inflammatory stress, introducing powerful immune-modulating drugs can sometimes lead to unpredictable reactions in other systems, like the liver. It highlights the potential risks of focusing solely on suppressing one part of a complex, dysregulated immune system without addressing the underlying reasons why the system is dysregulated in the first place.

The HS Armor Philosophy: Building Resilience from Within

This brings us back to the core philosophy we live by in the HS Armor community. We see pharmaceuticals like Adalimumab as potentially necessary shields, particularly during severe flares, but not as the foundation of health.

Our approach focuses upstream, on putting out the inflammatory fire itself. At HS Armor, we focus on highly effective evidence-based nutrition and lifestyle change, and natural therapies and practices. This involves systematically identifying and removing your personal inflammatory triggers (often dietary), calming the nervous system through stress management, optimizing sleep, and supporting the body with targeted natural compounds.

The goal isn’t just to manage HS; it’s to build such a strong foundation of health and resilience that the fire dies down, making the smoke alarms, and the powerful drugs needed to silence them, less necessary, or ideally, completely unnecessary. This approach inherently carries far less risk of systemic side effects like DILI because it works with the body’s natural healing mechanisms rather than forcefully suppressing one part of its defense system.

Key Takeaways

If you’re considering or currently using Adalimumab for HS, here are the crucial points from this research:

• Liver Injury is a Possible Risk: Adalimumab can cause drug-induced liver injury (DILI) in HS patients, an occurrence the authors note hasn’t been specifically described before in HS literature.
• Onset is Unpredictable: Liver problems can arise very quickly after starting the drug or years later, making vigilance essential.
• Monitoring Matters: Regular liver enzyme monitoring, especially early in treatment, is crucial to catch potential issues promptly.
• Highlights Treatment Limitations: These cases underscore that even effective symptom-suppressing drugs have limitations and potential serious side effects.
• Root Cause is Key: The safest and most sustainable path to long-term health involves addressing the underlying systemic inflammation that drives HS through foundational, natural strategies.

Conclusion: Empowerment Through Awareness

This research is not a reason to panic, but a call for informed awareness. Adalimumab remains a valuable tool in the fight against severe HS. However, these cases serve as a critical reminder that it is a powerful intervention with potential systemic consequences. They powerfully illustrate why relying solely on suppressing symptoms, on silencing the smoke alarm, is an incomplete strategy.

The journey to true, lasting remission from Hidradenitis Suppurativa involves looking deeper. It requires us to ask why the inflammation is happening and to address those root causes. By focusing on building a resilient foundation of health through nutrition, lifestyle, and natural therapies, we not only work towards healing our skin but also protect our overall well-being, reducing the need for interventions that carry risks like DILI. You have the power to influence your health from the inside out. Healing is possible.

Reference

[1] Caballero-Linares CF, Bianca C, Alfageme F. (2025). Hepatotoxicity Associated with Adalimumab in Hidradenitis Suppurativa: A Report of Two Cases of Drug-Induced Liver Injury. Dermatol Pract Concept, 15(3), 5320. https://doi.org/10.5826/dpc.1503a5320

Important Medical Disclaimer

1. Not Medical Advice: All content and information on this website is for informational and educational purposes only. It does not constitute medical advice and is not a substitute for professional diagnosis, treatment, or consultation with a qualified healthcare provider.

2. My Role and Qualifications: I am a biomedical scientist and PhD candidate and share information from that perspective, combined with my personal experience as a patient with Hidradenitis Suppurativa. However, I am not a medical doctor, physician, or registered healthcare professional. Do not consider our relationship a doctor-patient relationship.

3. Consult Your Doctor: Always seek the advice of your medical doctor or another qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. If you suspect you are experiencing a medical emergency, or a severe infection, do not rely on this website or the HS Armor community, please call your local emergency services or go to the nearest emergency room immediately.

4. A Critical Warning on Medication: Pharmaceutical drugs are a crucial tool in managing Hidradenitis Suppurativa for many people. Under absolutely no circumstances should you ever alter, reduce, or stop taking your prescribed medication without the explicit direction of the doctor who prescribed it. Doing so can be dangerous. Always consult with your doctor before doing anything related to your treatment plan.

5. No Liability: Your use of this website and reliance on any information provided is solely at your own risk.

6. Individual Results May Vary: Every patient’s biological baseline, genetics, and adherence to the protocol is different. Therefore, I cannot guarantee specific results, cures, or timelines for your Hidradenitis Suppurativa.

7. Scientific and Expressive Freedom: The articles published on this blog are distinct from formal peer-reviewed academic literature. They serve as an independent platform for my personal viewpoints, scientific hypotheses, and philosophical reflections as an independent scientist and HS patient. While grounded in biomedical research, I exercise a degree of expressive freedom to translate rigid academic data into insights from a patient perspective. These writings are my personal meditations on the science of HS and should be read as my individual perspective, not as universally accepted clinical consensus or formal peer-reviewed literature.